#United States #healthcare #Lexington #Curis #emavusertib

Curis, Inc. Q4 2025 Business Update

On March 19, 2026, Curis, Inc. (NASDAQ: CRIS), a biotechnology firm dedicated to developing emavusertib (CA-4948), delivered a comprehensive update regarding its quarterly financial performance and operational progress, specifically for the period that concluded on December 31, 2025. The company's focus remains on the advancement of therapies for hematologic malignancies, underscoring the significance of emavusertib as both an IRAK4 and FLT3 inhibitor.

Key Operational Updates

TakeAim Lymphoma Trials

In November 2025, notable presentations were made at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO), where Dr. Lakshmi Nayak from Dana-Farber Cancer Institution highlighted findings from the ongoing TakeAim Lymphoma study. The data presented showcased promising outcomes from patients treated with a combination of emavusertib and the BTK inhibitor, ibrutinib, in cases of relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL). The results are notable:

• - Every patient who was naive to BTK inhibitors achieved an objective response, translating to a 100% objective response rate.
• - In contrast, 37% of patients who had previously been treated with BTK inhibitors responded positively.
• - The duration of treatment for responders varied widely, highlighting the drug's variable efficacy in individual cases.

Dr. Cecilia Merrigan from the Mayo Clinic also presented data on Secondary CNS Lymphoma patients, indicating the positive impact emavusertib has when used alongside ibrutinib. One patient achieved a complete response, while another experienced stable disease, showcasing the efficacy of combination therapies in addressing challenging cases.

Curis is actively enrolling more patients into this trial, aiming to gather sufficient data to support accelerated regulatory approvals in both the United States and Europe, given that emavusertib has already attained orphan drug status from both the FDA and EMA for PCNSL.

TakeAim CLL Studies

Furthering its commitment to improving treatment for various hematological conditions, Curis initiated a Phase 2 study for Chronic Lymphocytic Leukemia (CLL) utilizing emavusertib in combination with zanubrutinib, another BTK inhibitor. This innovative approach aims to block NF-kB pathways critical in CLL and Non-Hodgkin Lymphoma (NHL). Previous studies highlighted the potential for deeper remissions in NHL when employing this dual blockade strategy. The goal is to transition these promising results into the clinical management of CLL, where standard BTK inhibitor treatments yield only partial responses.

Acute Myeloid Leukemia (AML) Insights

At the 67th ASH Annual Meeting, Dr. Christina Papayannidis detailed early findings from a triplet trial that incorporated emavusertib into the treatment of AML patients who had achieved complete remission but remained MRD-positive. The research suggests that combining emavusertib with azacitidine and venetoclax may offer substantial improvements in treatment outcomes, emphasizing the drug's potential utility in overcoming residual disease challenges.

Financial Results Overview

In terms of financial performance, Curis has reported a notable recovery. For the fiscal year ended December 31, 2025, the company incurred a net loss of $7.6 million, with a loss per share of $0.58, signaling a significant improvement from a loss of $43.4 million in 2024. Strikingly, the fourth quarter of 2025 saw Curis reporting a net income of $19.4 million, indicating a strong turnaround due in part to strategic asset sales and reduced operational costs.

Revenue for 2025 totaled $9.4 million, mainly driven by royalties from partnerships concerning Erivedge, although revenues for the fourth quarter decreased year-over-year. This reflects a transitionary phase as the company pivots towards its clinical programs.

Despite ongoing challenges in research and development expenditures and administrative expenses, Curis has managed to streamline its costs effectively. Total R&D expenses decreased to $28.3 million, underscoring Curis's commitment to optimizing its resources in the quest for developing groundbreaking treatments.

Corporate Financing and Cash Position

On January 9, 2026, Curis finalized a significant private placement yielding gross proceeds of up to $80.8 million, including an immediate influx of approximately $20.2 million. These funds are expected to nourish Curis’s development pipeline through at least the second half of 2027, enabling the continuation of vital clinical trials and operational activities.

Conclusion

Curis, Inc. stands at a pivotal moment within its operational framework, showcasing significant advancements in the clinical landscape for hematologic malignancies while demonstrating a positive correction in its financial trajectory. The community eagerly awaits further outcomes from its ongoing studies, aiming to foster new paradigms in the treatment of challenging cancers like PCNSL and CLL. The management's upcoming conference call will likely provide additional insights into these developments and future directions.